---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-004927"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T02:59:08.375416+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Grace Therapeutics reports Q3 FY2026 net loss of $2.3M; cash $18.7M; FDA PDUFA date April 23, 2026 for GTx-104

## Summary
- Net loss of $2.3M ($0.14 per share) improved from $4.2M loss ($0.36 per share) in prior year quarter.
- FDA set April 23, 2026 as PDUFA target date for GTx-104 NDA for aSAH treatment.
- Cash and equivalents $18.7M as of Dec 31, 2025; company believes sufficient for 12+ months.
- Phase 3 STRIVE-ON trial data presented; GTx-104 showed 19% reduction in hypotension vs. oral nimodipine.
- Raised $4.0M through warrant exercises at $3.003/share; 1.35M shares issued.

## SEC filing metadata
- accession: 0001140361-26-004927
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000114036126004927/0001140361-26-004927-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000114036126004927/ef20064916_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-004927
- JSON: https://secwatch.observer/filing/0001140361-26-004927.json
- Plain text: https://secwatch.observer/filing/0001140361-26-004927.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.